Abbott touts Xience DES study results

The Xience Sierra is one of nine Xience everolimus-eluting cardiovascular stents. A pair of studies […]

The Xience Sierra is one of nine Xience everolimus-eluting cardiovascular stents.

A pair of studies of Abbott’s Xience drug-eluting stent showed no difference between shorter courses of treatment with dual antiplatelet therapy (DAPT) compared with 12 months of DAPT following implantation of the XIENCE drug-eluting stent (DES) in patients who are at a high risk of bleeding.

Abbott presented the late-breaking data today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. Late-breaking results from the Short DAPT program of clinical trials evaluated findings from both the XIENCE 28 (1,605 patients) and XIENCE 90 (2,047 patients) studies.

DAPT is routinely prescribed after coronary stent implantation to help prevent clotting, but DAPT can also increase the risk of bleeding complications in some patients. The new late-breaking Short DAPT data showed no increase in ischemic events with shorter durations of DAPT for patients who require stenting, but who may adversely respond to blood-thinning medications.

Get the full story on our sister site, MassDevice.

 
Original Article: (https://www.drugdeliverybusiness.com/abbott-touts-xience-des-study-results/)